Interestingly, alemtuzumab treatments have significantly stronger effects than the treatments with IFN-β to stabilize or improve disability during the MS progression and even after 7-year follow-up (14, 16, 17). This evidence concerns the gene IFNB1 and myeloid sarcoma.